General information:
Substance group: Antiepileptic drug ATC: N03AD01
Trade names: Ethosuximid-*®, Petnidan®, Suxilep ®
available dosages: hard capsules 250 mg, soft capsules 250 mg, solution for taking 50 mg/mL
Reference ranges:
40 – 100 mg/L
Toxic plasma levels: >150 mg/L
Pharmacokinetics:
T1⁄2 : 40 – 60 h (children: 30 – 50 h)
Tmax : 1 – 4 h
Bioavailability: approx. 95%
Protein binding: 10% Clearance: 13 mL/min
Excretion: predominantly renal
Metabolism: hepatic
Distribution volume: 0.7 L/kg
Time to steady state: 8 – 10 days
Sampling:
Material: Serum (Monovette brown) Minimum volume for analysis: 500µl
Recommendation: trough level (directly before the next intake)
Requirement (internal): about Orbis requirement (external):
Analytics:
Test principle: Gas chromatography with flame ionization detector (GC-FID) or immuno-assay
Protein precipitation and liquid-liquid extraction with chloroform and hydrochloric acid, chromatographic separation, thermal ionization and measurement of conductivity
Analysis system: GC, flame ionization detector
Findings release: on the same working day, via LIMS
DrugBank: https://go.drugbank.com/drugs/DB00593